Advance of Mechanisms and Clinical Applications about Rapamycin for Treating Immune Mediated Hemocytopenia--Review / 中国实验血液学杂志
Journal of Experimental Hematology
;
(6): 1836-1840, 2018.
Article
in Chinese
| WPRIM
| ID: wpr-774376
ABSTRACT
Immune-mediated hemocytopenia is a common cytopenic diseases without bone marrow hematopoietic abnormalities, the patient's quality of life is significantly reduced when first-line treatments are ineffective. Rapamycin, possesses a clear mechanism of targeting mTOR protein, can upregulate regulatory T cells and induces apoptosis of specific cells, by regulating the lymphocyte subsets, so as to treat various types of immune-mediated hemocytopenia with a certain therapeutic effect. In this reviews, the action mechanism and clinical application of rapamycin in immune thrombocytopenia(ITP), autoimmune hemolytic anemia(AIHA), acquired aplastic anemia and autoimmune lymphoproliferative syndrome(ALPS) etc. are summarized.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Quality of Life
/
T-Lymphocytes, Regulatory
/
Sirolimus
/
Therapeutic Uses
/
TOR Serine-Threonine Kinases
/
Anemia, Aplastic
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS